9/1/2026
Barrow, ASU launch clinical trial for ibogaine in the US
The study aims to explore ibogaine's potential for treating PTSD and addiction.
Topic archive
arizona state university
10 stories
8/21/2026
Johnson & Johnson invests in Delix Therapeutics
Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.
8/19/2026
Arizona study to explore ibogaine for PTSD, brain injuries
Barrow Neurological Institute to test ibogaine's safety and efficacy in a state-funded trial.
8/19/2026
Arizona funds $5M ibogaine study for brain injuries
Barrow Neurological Institute to explore ibogaine's potential for PTSD and brain injuries.
8/10/2026
Barrow Neurological Institute secures $5M for ibogaine brain injury trial
Arizona funds first U.S. ibogaine trial for traumatic brain injuries, starting 2027.
8/7/2026
Arizona funds $5M ibogaine trial for brain injury
Study explores ibogaine's potential for TBI, amid safety concerns and federal illegality.
8/6/2026
Barrow Neurological Institute secures $5M for ibogaine TBI trial
The trial will explore ibogaine's potential to treat traumatic brain injury, starting in 2027.
8/6/2026
Barrow Institute gets $5M for ibogaine brain injury trial
The trial will explore ibogaine's potential in treating chronic TBI symptoms.
8/6/2026
Barrow begins ibogaine trial for brain injury recovery
Arizona-funded study explores ibogaine's potential for neurological disorders.
8/5/2026
Barrow Neurological Institute receives $5M for ibogaine study
Grant supports research into ibogaine's effects on neurological disorders.